Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $16.30 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-02-26
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2020-03-31 was $11.23, a 4.99% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2019-09-30 was $8.73, a 117.71% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2019-06-30 was $9.35, a 230.39% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2019-03-31 was $11.82, a 307.59% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $16.30, a 30.96% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $23.61, a 2.84% decline from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $24.30, a 1.42% increase from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $23.96, a 102.54% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $16.30 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $23.61 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $24.30 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $23.96 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $11.83 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $11.51 10-K · filed 2023-02-27 | |||
| 2020-03-31 | $11.23 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $10.09 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $8.73 10-Q · filed 2019-11-06 | $10.25 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $9.35 10-Q · filed 2019-08-06 | $10.80 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $11.82 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $3.85 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $4.01 10-Q · filed 2019-11-06 | $3.29 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $2.83 10-Q · filed 2019-08-06 | $2.87 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $2.90 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $1.94 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $2.43 10-Q · filed 2018-11-08 | $2.08 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $1.29 10-Q · filed 2018-08-09 | $1.16 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $1.06 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $1.36 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |